Table 2 Predictors of inferior response and survival in 183 JAK2 inhibitor-naive patients with myelofibrosis receiving JAK2 inhibitors in the context of clinical trials.

From: Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Variables

Spleen response

Anemia response in transfusion-dependent patients

Overall survival

Leukemia-free survival

N evaluable = 166

N evaluable = 66

N evaluable = 183

N evaluable = 183

Univariate/Multivariate P-value Odds ratio

Univariate/Multivariate P-value Odds ratio

Univariate/Multivariate P-value HR (95% CI)

Univariate/Multivariate P-value HR (95% CI)

Age > 65 years

0.62

0.64

<0.01/<0.01

3.5(2.2–5.7)

0.21

Male gender

0.11/0.72

0.37

0.42

0.79

PMF vs Post-ET/PV MF

0.34

1.0

0.65

0.92

Hemoglobin < 10 g/dl.

0.28

0.62

0.15

0.49

Leukocyte count > 25 × 109/l

0.40

0.65

0.11

0.74

Peripheral blasts ≥ 1%

0.18

0.13

0.61

0.97

Platelet count < 100 × 109/l

0.29

<0.01/<0.01

0.94

0.27

Transfusion-dependence

1.0

 

<0.01/<0.01

2.1 (1.3–3.3)

0.39

Favorable vs unfavorable karyotype

0.17

0.40

0.02/0.26

0.89

Absence of type 1/like CALR mutation

0.13/0.18

0.19

<0.01/<0.01

2.8 (1.3–5.8)

0.15

Presence of ASXL1/SRSF2 mutations

0.06/0/04

OR 0.43

0.49

0.01/0.04

1.6 (1.01–2.5)

0.38

Type of JAK2 inhibitor

<0.01/0.01

0.07/0.02

0.31

0.33

Ruxolitinib vs fedratinib

<0.01/0.01

OR 0.08

   

Ruxolitinib vs momelotinib

0.10/0.04

OR 0.34

Ruxolitinib vs BMS JAK inhibitor

0.02/0.03

OR 0.19

Fedratinib vs momelotinib

<0.01/0.07

OR 5.3

0.04/0.02

OR 0.07

  1. Bold values indicates statistical significant P values (P < 0.05).
  2. PMF primary myelofibrosis, post-ET MF post-essential thrombocythemia myelofibrosis, post-PV Post polycythemia myelofibrosis.
Back to article page